Menu
Search
|

Menu

Close
X

SCYNEXIS Inc SCYX.OQ (NASDAQ Stock Exchange Global Market)

0.53 USD
-0.00 (-0.00%)
As of Dec 12
chart
Previous Close 0.53
Open 0.59
Volume 129,148
3m Avg Volume 39,993
Today’s High 0.61
Today’s Low 0.52
52 Week High 2.44
52 Week Low 0.52
Shares Outstanding (mil) 47.97
Market Capitalization (mil) 36.94
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.314
FY17
-0.929
FY16
-1.696
FY15
-2.198
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
30.88
Price to Sales (TTM)
vs sector
143.73
21.76
Price to Book (MRQ)
vs sector
1.30
4.53
Price to Cash Flow (TTM)
vs sector
--
22.24
Total Debt to Equity (MRQ)
vs sector
53.68
13.39
LT Debt to Equity (MRQ)
vs sector
27.32
9.53
Return on Investment (TTM)
vs sector
-52.69
13.80
Return on Equity (TTM)
vs sector
-79.79
15.29

EXECUTIVE LEADERSHIP

Pamela Kirby
Chairman of the Board, Since
Salary: --
Bonus: --
Marco Taglietti
President, Chief Executive Officer, Director, Since 2015
Salary: --
Bonus: --
Eric Francois
Chief Financial Officer, Since 2015
Salary: --
Bonus: --
Scott Sukenick
General Counsel, Since 2017
Salary: --
Bonus: --
David Angulo
Chief Medical Officer, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

1 Evertrust Plz Fl 13
JERSEY CITY   NJ   07302-3051

Phone: +1201.8845485

SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.

SPONSORED STORIES